Company Description
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment.
Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.
The company’s pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine, which is in Phase 2 clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.
It also develops non-oncology drugs consisting of PCS12852 that is in Phase 2B clinical trials for treatment of gastroparesis; and PCS499 for the treatment of glomerular disease.
The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2017 and is based in Hanover, Maryland.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | George Ng |
Contact Details
Address: 7380 Coca Cola Drive, Suite 106 Hanover, Maryland 21076 United States | |
| Phone | 443 776 3133 |
| Website | processapharmaceuticals.com |
Stock Details
| Ticker Symbol | PCSA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001533743 |
| CUSIP Number | 74275C205 |
| ISIN Number | US74275C3043 |
| Employer ID | 45-1539785 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| George K. Ng Esq., J.D. | Chief Executive Officer and Director |
| Dr. David Young Ph.D., Pharm.D. | Co-Founder, President of Research and Development and Director |
| Dr. Sian E. Bigora Ph.D., Pharm.D. | Co-Founder and Chief Development and Regulatory Officer |
| Patrick Lin | Co-Founder, Chief Business and Strategy Officer |
| Wendy J. Guy | Co-Founder, Chief Administrative Officer and Corporate Secretary |
| Russell L. Skibsted M.B.A. | Chief Financial Officer |
| Dr. Steven Cha M.D. | Senior Vice President of Clinical Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | DEF 14A | Other definitive proxy statements |
| May 12, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 20, 2025 | 10-K | Annual Report |
| Feb 11, 2025 | 8-K | Current Report |
| Feb 10, 2025 | 8-K | Current Report |
| Jan 30, 2025 | 8-K | Current Report |
| Jan 29, 2025 | 424B4 | Prospectus |
| Jan 27, 2025 | EFFECT | Notice of Effectiveness |